<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01599130</url>
  </required_header>
  <id_info>
    <org_study_id>Zhangyufeng</org_study_id>
    <nct_id>NCT01599130</nct_id>
  </id_info>
  <brief_title>Efficacy of Peg-interferon α-2a in Hepatitis B Patients Treated by Entecavir Without HBeAg Loss</brief_title>
  <official_title>The Efficacy of Peg-interferon α-2a in HBeAg (+) Chronic Hepatitis B Patients Who Have Been Treated by Entecavir for 48 Weeks But Without HBeAg Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For HBeAg (+) hepatitis B patients who have been treated by entecavir for 48 weeks but
      without HBeAg loss, switching to peg-interferon may increase the response rate. In the
      investigators study, patients were divided into two groups. In Group A, patients continued
      entecavir for another 72 weeks. In Group B, patients switched to peg-interferon-2a
      monotherapy for 48 weeks, then followed up 24 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For HBeAg positive hepatitis B patients who have been treated by entecavir for 48 weeks but
      without HBeAg loss, switching to peg-interferon may increase the response rate. In our study,
      patients without HBeAg loss to 48 weeks entecavir treatment were divided into two groups. In
      Group A, patients continued entecavir for another 72 weeks. In Group B, patients switched to
      peg-interferon-2a monotherapy for 48 weeks, then followed up 24 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HBeAg sericonversion rate</measure>
    <time_frame>72 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HBeAg loss rate</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBeAg quantification dynamic change</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAg loss rate</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAg seroconversion rate</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAg quantification dynamic change</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT normalization rate</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>entecavir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients continue to use entecavir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>peg-interferon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients switch to sequential peg-interferon α-2a</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>entecavir 0.5mg per day</description>
    <arm_group_label>entecavir</arm_group_label>
    <other_name>Baraclude</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a</intervention_name>
    <description>Peginterferon alfa-2a 180ug per week</description>
    <arm_group_label>peg-interferon</arm_group_label>
    <other_name>Pagasys</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 50 years old

          -  HBsAg(+) and HBeAg(+) for over 6 months before entecavir treatment

          -  Treated by entacavir for 48 weeks with HBeAg seroconversion

        Exclusion Criteria:

          -  Pregnant women

          -  Decompensated liver disease

          -  Combination infection of HCV, HAV, or HEV

          -  Combination infection of HIV

          -  Any contraindication of interferon α
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhiliang Gao</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Third Affliated Hospital of Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Third Affliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yufeng Zhang, master</last_name>
      <phone>+862085253333</phone>
      <email>zhanlianh@163.com</email>
    </contact>
    <contact_backup>
      <phone>+862085253333</phone>
    </contact_backup>
    <investigator>
      <last_name>Zhiliang Gao, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2012</study_first_submitted>
  <study_first_submitted_qc>May 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2012</study_first_posted>
  <last_update_submitted>May 14, 2012</last_update_submitted>
  <last_update_submitted_qc>May 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Gao zhiliang</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Hepatitis B</keyword>
  <keyword>sequential peg-interferon-2a to entecavir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

